4. Reynolds K, Gu D, Muntner P, et al. Geographic variations in the prevalence, awareness, treatment and control of hypertension in China. J Hypertens. 2003;21:1273–1281.

5. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.

6. Zimmet P, Boyko EJ, Collier GR, de Court. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann NY Acad Sci. 1999;892:25–44.

7. Grundy SM, Abate N, Chandalia M. Diet composition and the metabolic syndrome: what is the optimal fat intake? Am J Med. 2002;113 Suppl 9B:25S–29S.

8. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation. 2003;108:1546–1551.

9. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715–722.

10. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia. 2001;44:1148–1154.

11. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 2003;26:3153–3159.

12. World Health Organization, International Association for the Study of Obesity International Obseity Task Force. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Sydney: Health Communications; 2000.